DDInter557 DDInter843
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Griseofulvin
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Griseofulvin
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Griseofulvin
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} (Compound) resembles {v} (Compound) Methysergide
Methysergide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound)
Dihydroergotamine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Griseofulvin (Compound)
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Dihydroergotamine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound)
Dihydroergotamine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Dihydroergotamine (Compound) resembles Bromocriptine (Compound) and Bromocriptine (Compound) resembles Methysergide (Compound) and Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Griseofulvin